The FDA Approves New Drug Kisunla to Slow Alzheimer’s Progression

For families like Katherine Fillmore’s, the news of a loved one being diagnosed with Alzheimer’s is devastating. Watching her mother, Amelia, slowly fade away has been a heartbreaking journey. However, there is now a glimmer of hope on the horizon with the FDA’s approval of a new drug called Kisunla, developed by Eli Lilly.

Donanemab, as it’s known in the medical world, is a groundbreaking treatment that can significantly slow the progression of Alzheimer’s in its early stages. Dr. Joseph Masdeu, Director of the Nantz National Alzheimer’s Center at Houston Methodist, describes this approval as a major advancement in Alzheimer’s treatment.

While the drug may come too late for Fillmore’s mother, it offers hope for families just beginning their Alzheimer’s journey. It underscores the importance of early diagnosis and intervention. Dr. Carlos Julian Martinez-Menendez, a behavioral neurologist at UTHealth, emphasizes that early detection can improve quality of life and delay disease progression.

For those seeking information or support, the Alzheimer’s Association offers a free 24/7 Helpline at 800-272-3900. This resource can provide guidance and connect families with local resources.

As we look toward the future, Kisunla represents a new chapter in the fight against Alzheimer’s. It’s a beacon of hope for families facing this challenging disease, offering the possibility of a brighter future for those affected by Alzheimer’s.

For more updates, follow Marcelino Benito on social media: Facebook | Twitter | Instagram